Wuhan YZY Biopharma Co., Ltd.
Wuhan YZY Biopharma is a Hong Kong-listed (HKEX: 2496) bispecific-antibody developer working in oncology, ophthalmology and autoimmune disease. China's NMPA accepted the marketing application for its lead antibody M701 in malignant ascites in May 2026.
| Headquarters | Wuhan, China |
|---|---|
| Listing | HKEX:02496 |
| Lead asset / stage | M701 NDA accepted — China |
| Latest event | The NMPA accepted the M701 marketing application for malignant ascites. |